Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445398 | 1.00 | NPSR1 (0.50) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27468145 | 0.98 | NPSR1 (0.48) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL17958 | 0.97 | NPSR1 (0.52) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL1928676 | 0.92 | — | — | |
| SCHEMBL25616531 | 0.89 | FFAR3 (0.50) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL25616533 | 0.89 | FFAR3 (0.50) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL8175853 | 0.89 | FFAR3 (0.50) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL283125 | 0.89 | — | — | |
| SCHEMBL15800283 | 0.86 | NPSR1 (0.40) | NPSR1CYP3A4MEN1KMT2AALDH1A1 | |
| SCHEMBL31443223 | 0.84 | CYP3A4 (0.40) | NPSR1CYP3A4MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022664-A1 | PROCESS FOR TREATING POLYESTER METHANOLYSIS DEPOLYMERIZATION PRODUCT STREAMS | EASTMAN CHEMICAL COMPANY (US) | 2023-01-26 | — | — | US | claimed |
| CN-115103875-A | Method for treating polyester methanolysis depolymerization product stream | 伊士曼化工公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114105748-A | Preparation method, prepared ketene compound and application of compound | 万华化学集团股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | claimed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | claimed |
| US-5866564-A | STABILITY | SANKYO COMPANY, LIMITED (JP) | 1999-02-02 | — | — | US | claimed |
| EP-0518558-B1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | SANKYO CO (JP) | 1998-09-02 | — | — | EP | claimed |
| US-5712267-A | Carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY,. LIMITED (JP) | 1998-01-27 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0337637-B1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | SANKYO CO (JP) | 1994-11-30 | — | — | EP | claimed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | claimed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | claimed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | claimed |
| CN-122094932-A | Amide substituted cycloalkyl compound, preparation method and medical application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-4232139-A | Process for producing polymers or copolymers of olefins containing at least 3 carbon atoms | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1980-11-04 | — | — | US | disclosed |
| US-4221894-A | MAGNESIUM HALIDE, TITANIUM, ORGANOALUMINUM, ESTER | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1980-09-09 | — | — | US | disclosed |
| US-4143223-A | TITANIUM, HALOGEN, ALUMINUM, ESTER AND AN ALCOHOL | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022664-A1 | PROCESS FOR TREATING POLYESTER METHANOLYSIS DEPOLYMERIZATION PRODUCT STREAMS | ADH1A, ADH1C, ADH5 | NPSR1 2612/4885CYP3A4 327/4885MEN1 3701/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | NPSR1 2964/4885CYP3A4 262/4885MEN1 3600/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | NPSR1 2304/4885CYP3A4 1103/4885MEN1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.